



## **Idera to Present at the 15th Annual Needham Healthcare Conference**

**April 11, 2016 2:30 PM EDT**

CAMBRIDGE, Mass. and EXTON, Pa., April 11, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Executive Officer, Vincent Milano will present at the 15<sup>th</sup> Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 3:40 p.m. Eastern Time at the Westin Grand Central Hotel in New York City.

Live audio webcast of Idera's presentations will be accessible in the Investors and Media section of Idera's website at <http://www.iderapharma.com>. Archived versions will also be available on the Company's website after the event for 90 days.

### ***About Idera Pharmaceuticals***

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera's proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit [www.iderapharma.com](http://www.iderapharma.com).

### **Investor and Media Contact**

Robert Doody

VP, IR & Corporate Communications

617-679-5515 (office)

484-639-7235 (mobile)

[rdoodu@iderapharma.com](mailto:rdoodu@iderapharma.com)



Idera Pharmaceuticals, Inc.